Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Strictly Buy and Sell Set Ups -- Ignore unavailable to you. Want to Upgrade?

To: - with a K who wrote (2353)	2/22/2005 11:18:56 AM
From: chowder	Respond to of 13449

The chart didn't provide any clues. This will often happen with news related events. With action like IPXL is showing today, it provides good opportunities for those who like to do intraday trades. Real time 5 minute chart will kick in a buy signal at $17.54. I'm not sure the day's highs will be hit though from this signal. May get a better signal after 2PM for those wanting an overnight or longer term position. If you are already in, very nice result so far. Congratulations. dabum

To: - with a K who wrote (2353)	2/22/2005 8:39:36 PM
From: - with a K	Read Replies (2) \| Respond to of 13449

IPXL in Forbes story on acquisition possibility. It finished up 7.13%, and still strong TRLG was up 2.86% EZA gapped up on nice volume, up 3.45% The rest of my portfolio is filled with red, but these three help. Glad I sold CHS and a few others. Potential Takeover Targets In Specialty Pharma 02.22.05, 4:20 PM ET Credit Suisse First Boston expects merger activity to intensify in the specialty pharmaceuticals sector after Novartis (nyse: NVS - news - people ) said it would buy Eon Labs (nasdaq: ELAB - news - people ) and Hexal for $8.3 billion. "We believe these acquisitions could signal the start of further consolidation in the generics sector," said CSFB. "To the extent Novartis' actions trigger further M&A in the sector, we believe Impax Laboratories (nasdaq: IPXL - news - people ), and to a lesser extent, Watson Pharmaceuticals (nyse: WPI - news - people ), remain attractive consolidation targets in the context of the Eon Labs takeover." CSFB said Impax Labs possesses an attractive flow of new products while Watson has favorable valuation attributes.